Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2013 Financial Results

Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and
Full Year 2013 Financial Results

Conference Call Scheduled for March 5, 2014 at 4:30 pm ET

SAN DIEGO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a
pharmaceutical company developing and commercializing products for the
treatment of pain-related conditions and central nervous system disorders,
today announced it will release financial results for the fourth quarter and
full year ended December 31, 2013, after the market closes on Wednesday, March
5, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30
p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations
website at ir.zogenix.com, and to participate, please dial 877-474-9506 (U.S.)
or 857-244-7559 (International); participant passcode: 23384178.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley,
President Stephen J. Farr, Ph.D., and Executive Vice President and Chief
Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning March 5, 2014 at
8:30 p.m. ET (5:30 p.m. PT) until March 12, 2014, by dialing 888-286-8010
(U.S.) or 617-801-6888 (International); passcode: 95697181. A replay of the
webcast will also be accessible on the Investor Relations website for one
month, through April 5, 2014.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville,
California, is a pharmaceutical company committed to developing and
commercializing therapies that address specific clinical needs for people
living with pain-related conditions and central nervous system disorders who
need innovative treatment alternatives to help them return to normal daily
functioning. The Company has commercialized two products using technology to
enhance the patient experience and has a development pipeline that includes a
once-monthly subcutaneous injection for schizophrenia. More information about
Zogenix is available at www.zogenix.com

                                     FPR

CONTACT: Investors
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com
        
         Media
         Aaron Estrada | The Ruth Group
         646-536-7028 | aestrada@theruthgroup.com
 
Press spacebar to pause and continue. Press esc to stop.